{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=9&state=Michigan",
    "query": {
      "state": "Michigan",
      "city": "Detroit",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 7237,
    "total_pages": 724,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=10&state=Michigan&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=8&state=Michigan&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T07:45:29.673Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04691375",
      "title": "A Study of PY314 in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Gynecologic Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Lung Adenocarcinoma",
        "Renal Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "PY314",
          "type": "DRUG"
        },
        {
          "name": "Combination Therapy: PY314 + Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2020-10-29",
      "completion_date": "2023-09-22",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04691375"
    },
    {
      "nct_id": "NCT00157157",
      "title": "Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "Up to 6 Years"
      },
      "enrollment_count": 66,
      "start_date": "2004-04-01",
      "completion_date": "2009-09-11",
      "has_results": true,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00157157"
    },
    {
      "nct_id": "NCT01652157",
      "title": "Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fibrosing Colonopathy"
      ],
      "interventions": [
        {
          "name": "ULTRESA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PANCREAZE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CREON",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ZENPEP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "other non-sponsor pancreatic enzyme replacement therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PERTZYE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "No pancreatic enzyme replacement therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "0 Months to 99 Years"
      },
      "enrollment_count": 17,
      "start_date": "2012-07-31",
      "completion_date": "2020-04-08",
      "has_results": false,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 123,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652157"
    },
    {
      "nct_id": "NCT01467700",
      "title": "Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Depressive Episode"
      ],
      "interventions": [
        {
          "name": "Ramelteon SL",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 490,
      "start_date": "2011-12",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-05-16",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 141,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 137 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01467700"
    },
    {
      "nct_id": "NCT01794000",
      "title": "A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Prasugrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 341,
      "start_date": "2013-04",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 20,
      "location_summary": "Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01794000"
    },
    {
      "nct_id": "NCT00849472",
      "title": "Treatment With Pazopanib for Neoadjuvant Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Breast"
      ],
      "interventions": [
        {
          "name": "doxorubicin + cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel + pazopanib",
          "type": "DRUG"
        },
        {
          "name": "surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "pazopanib monotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 101,
      "start_date": "2009-07",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 137,
      "location_summary": "Decatur, Alabama • Huntsville, Alabama • Antioch, California + 97 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849472"
    },
    {
      "nct_id": "NCT03180619",
      "title": "Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2017-06-29",
      "completion_date": "2020-09-04",
      "has_results": true,
      "last_update_posted_date": "2021-09-27",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03180619"
    },
    {
      "nct_id": "NCT02269267",
      "title": "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myeloid, Chronic"
      ],
      "interventions": [
        {
          "name": "Imatinib (Stopping their TKI)",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib (Stopping their TKI)",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib (Stopping their TKI)",
          "type": "DRUG"
        },
        {
          "name": "Bosutinib (Stopping their TKI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2014-12-18",
      "completion_date": "2022-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-03-03",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 16,
      "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Lenox",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269267"
    },
    {
      "nct_id": "NCT03038100",
      "title": "A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1301,
      "start_date": "2017-03-08",
      "completion_date": "2022-08-12",
      "has_results": true,
      "last_update_posted_date": "2023-02-17",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 127,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 101 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038100"
    },
    {
      "nct_id": "NCT03664765",
      "title": "Novel by Upper Airway Respiratory Muscle Training to Treat OSA in Chronic SCI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "OSA",
        "SCI/D",
        "Upper Airway Exercise"
      ],
      "interventions": [
        {
          "name": "UA and RMT",
          "type": "OTHER"
        },
        {
          "name": "Sham exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 29,
      "start_date": "2019-01-01",
      "completion_date": "2022-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-10-28T07:45:29.673Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03664765"
    }
  ]
}